Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date: 2018-08-22

Last Posted Date: 2023-11-29

Lead Sponsor: Martin Schrappe

Target Recruit Count: 5000

Registration Number: NCT03643276

Locations: 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹
A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Placebo oral capsule
Drug: Prednisolone

First Posted Date: 2018-08-01

Last Posted Date: 2020-03-06

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 33

Registration Number: NCT03610685

Locations: 🇬🇧
Asthma and copd research centre, Glasgow, United Kingdom

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Phase 1

Completed

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Nivolumab
Drug: Etoposide
Drug: Prednisolone
Drug: Oncovin
Drug: Cyclophosphamide
Drug: Hydroxydaunorubicin

First Posted Date: 2018-07-16

Last Posted Date: 2024-10-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 18

Registration Number: NCT03586999

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Ramadan Fasting in Patients With Corticotrope Deficiency Treated Either by Hydrocortisone or by Prednisolone

Phase 4

Completed

Conditions: Fasting
Corticotropin Deficiency

Interventions: Drug: Prednisolone
Drug: Hydrocortisone

First Posted Date: 2018-07-13

Last Posted Date: 2019-04-29

Lead Sponsor: University Tunis El Manar

Target Recruit Count: 53

Registration Number: NCT03585829

Locations: 🇹🇳
University Tunis El Manar, Tunis, Tunisia

Treatment With Leflunomide in Patients With Polymyalgia Rheumatica

Phase 3

Conditions: Polymyalgia Rheumatica

Interventions: Drug: Leflunomide 20 mg
Drug: Prednisolone

First Posted Date: 2018-07-03

Last Posted Date: 2019-06-03

Lead Sponsor: Elisabeth Brouwer

Target Recruit Count: 94

Registration Number: NCT03576794

Locations: 🇳🇱
ZGT Almelo, Almelo, Netherlands
🇳🇱
University Medical Center Groningen, Groningen, Netherlands

The Value of Prednisolone With Aspirin Before Embryo Transfer in Intracytoplasmic Sperm Injection (ICSI) Cycles

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Acetyl Salicylic acid
Drug: prednisolone

First Posted Date: 2018-04-19

Last Posted Date: 2019-04-04

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 250

Registration Number: NCT03503227

Locations: 🇪🇬
KasralainiH, Cairo, Egypt

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: AZD9567
Drug: Prednisolone

First Posted Date: 2017-12-11

Last Posted Date: 2020-10-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT03368235

Locations: 🇸🇪
Research Site, Lund, Sweden

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: Glatiramer acetate
Drug: Beta-Interferon
Drug: Methylprednisolone
Drug: Ranitidine
Drug: Ceterizine
Drug: Dexchlorpheniramine
Drug: Paracetamol
Drug: Acyclovir
Drug: Prednisolone
Drug: Diphenydramine
Drug: Other H1 antagonist

First Posted Date: 2017-12-11

Last Posted Date: 2023-09-21

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 16

Registration Number: NCT03368664

Locations: 🇹🇷
Investigational Site Number :7920002, Ankara, Turkey
🇹🇷
Investigational Site Number :7920001, Ankara, Turkey
🇫🇷
Investigational Site Number :2500002, Strasbourg, France

and more 18 locations

Postoperative Oral Corticosteroids Following Tonsillectomy

Not Applicable

Conditions: Tonsillectomy

Interventions: Drug: Placebos
Drug: Prednisolone

First Posted Date: 2017-11-24

Last Posted Date: 2017-11-24

Lead Sponsor: Wayne State University

Target Recruit Count: 200

Registration Number: NCT03352115

The Norwegian Prednisolone in Early Psychosis Study

Phase 2

Terminated

Conditions: Schizophrenia and Related Disorders
Immune Suppression
Psychosis
Cognitive Change

Interventions: Drug: Prednisolone
Other: Placebo

First Posted Date: 2017-11-14

Last Posted Date: 2022-08-01

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 12

Registration Number: NCT03340909

Locations: 🇳🇴
Stavanger University Hospital, Stavanger, Norway
🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴
St. Olavs Hospital, Trondheim, Norway

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy